Please login to the form below

Not currently logged in
Email:
Password:

benralizumab

This page shows the latest benralizumab news and features for those working in and with pharma, biotech and healthcare.

FDA rejects GSK’s Nucala for COPD

FDA rejects GSK’s Nucala for COPD

Fasenra (benralizumab) and Teva’s Cinqair/Cinqaero (reslizumab).

Latest news

More from news
Approximately 8 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD)

  • Pharma deals in July 2015 Pharma deals in July 2015

    In Japan, AZ paid $45m for an option with Kyowa Hakko Kirin to commercialise benralizumab (currently in phase III for treatment of severe uncontrolled asthma and COPD) in Japan.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics